Hyperoll, Hyperion make up, sign deal

The multi-year pact brings to an end Hyperoll's patent infringement suit against Hyperion and allows for sharing of technologies between the two companies and for Hyperion to invest in Hyperoll stock.

By DANIEL KENNEMER
October 11, 2006 08:11

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Hyperoll Ltd., a producer of data processing and business intelligence software, said Tuesday it has signed a strategic cooperation agreement with business performance management (BPM) programming producer Hyperion Solutions, whereby Hyperion will integrate Hyperoll technologies into the latest generations of its products. The multi-year pact brings to an end Hyperoll's patent infringement suit against Hyperion and allows for sharing of technologies between the two companies and for Hyperion to invest in Hyperoll stock. A market source estimated the value of the deal at tens of millions of dollars. Hyperoll has its management headquarters in Mountain View, California and a technological development facility in Omer, north of Beersheba.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS